title: TIME for a successful cancer vaccine in NSCLC?
authors.affiliation: Department of Oncology, University of Alberta, Edmonton, AB TRG 2R3, Canada; Cross Cancer Institute, Edmonton, AB, Canada. Electronic address: charles.butts@albertahealthservices.ca.
authors.forename: Charles A
authors.initials: CA
authors.lastname: Butts
authors.affiliation: Department of Oncology, University of Alberta, Edmonton, AB TRG 2R3, Canada; Cross Cancer Institute, Edmonton, AB, Canada.
authors.forename: Randeep
authors.initials: R
authors.lastname: Sangha
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008214:Lymphocytes / Q000737:chemistry*; D008297:Male; D008562:Membrane Glycoproteins / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D008562:Membrane Glycoproteins